Quale sarebbe il prezzo per Abnova (Taiwan) Corporation (4133)

Il prezzo per Abnova (Taiwan) Corporation (4133) è $0.66300973

Qual è la capitalizzazione di mercato per Abnova (Taiwan) Corporation (4133)

La capitalizzazione di mercato per Abnova (Taiwan) Corporation (4133) è $40.15M

Abnova (Taiwan) Corporation (4133) Rapporto P/B

Abnova (Taiwan) Corporation specializes in the development and distribution of a comprehensive range of recombinant proteins and antibodies. The company's extensive product portfolio caters to diverse research and diagnostic applications, featuring specialized reagents for SARS-CoV/CoV-2, nucleic acids (both DNA and RNA), and various proteins and peptides. Their offerings further include items like DNAxPab, laboratory beads, dyes, cellular lysates, microscopic slides, antibody pairs and associated kits, as well as antibody and tissue arrays. Additionally, they provide in situ hybridization products, advanced laboratory systems and automation, GMP-grade and analyte-specific reagents, and solutions for in vitro diagnostics. Beyond these product lines, Abnova supplies a broad spectrum of antibody types, such as MaxPab, monoclonal, polyclonal, recombinant, conjugate, secondary/tag, IHC/pathology, and those specifically targeting circulating rare cells. The company also delivers integrated solutions and services, encompassing gene synthesis and cytogenetic analysis, peptide services, protein expression and conjugations, custom antibody generation, and assay development. Abnova (Taiwan) Corporation operates from its headquarters in Taipei, Taiwan.

Anno	Rapporto P/B	Cambia
Non abbastanza dati per le date fornite.

Anno

Rapporto P/B

Cambia

Non abbastanza dati per le date fornite.

Azienda	Rapporto P/B	Differenza del rapporto P/B	Il paese
Vertex Pharmaceuticals Incorporated VRTX.US	6.3419	-	US
Argenx SE ARGX.US	6.2413	-	NL
CSL Limited CSL.AX	2.5054	-	AU
Moderna, Inc. MRNA.US	3.7087	-	US
Lonza Group AG LONN.SW	-	-	CH

Azienda

Rapporto P/B

Differenza del rapporto P/B

Il paese